{"filings":[{"id":93901,"accession_number":"0001588978-26-000020","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT BioRobotics Reports Q1 2026 Revenue of $83.1M, Up 20% YoY; Net Loss Widens to $31.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $83.1M, +20% YoY; U.S. procedures 12,200, +30% YoY.","Sold 49 U.S. Hydros systems, ASP ~$485,000; U.S. install base 765 systems, +40% YoY.","FDA clearance of second-generation FirstAssist AI software for Aquablation therapy.","Full-year 2026 revenue guidance $390M-$410M, growth 27%-33%; adjusted EBITDA loss outlook $30M-$17M.","Net loss $31.6M vs $24.7M in prior year; adjusted EBITDA loss $18.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":83132000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105891,"accession_number":"0001588978-26-000013","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Appoints Daniel Puckett as new board member and Audit Committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 8 to 9 members; Puckett appointed effective March 5, 2026.","Puckett is an independent director and joins the Audit Committee.","He previously served as CFO of Shockwave Medical (2016-2024) and Ariosa Diagnostics.","His initial term expires at the 2027 annual meeting of stockholders.","Compensation follows standard non-employee director program; no related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105890,"accession_number":"0001588978-26-000007","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PROCEPT BioRobotics holds Investor Day; no specific data disclosed in 8-K exhibit excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor Day held Feb 26, 2026 at NASDAQ HQ; presentation furnished as Exhibit 99.1.","Full presentation content not available in this filing excerpt; no specific financial guidance or operational metrics provided.","Company directed to investor relations website for replay and additional details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105889,"accession_number":"0001588978-26-000002","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT BioRobotics Q4 rev $76.4M (+12% YoY), net loss $29.8M; FY26 guidance $390-410M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $76.4M (+12% YoY); U.S. procedures ~12,200 (+69% YoY).","Q4 net loss $29.8M vs $18.9M loss; adjusted EBITDA loss $19.0M vs $10.3M.","U.S. install base 718 systems (+42% YoY); handpiece ASP $3,340 (+5% sequentially).","FY 2026 revenue guidance $390-410M (27-33% growth); U.S. procedure growth 39-48%.","FY 2026 gross margin ~65%; operating expenses ~$350M; adj. EBITDA loss $30-17M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":308054000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122150,"accession_number":"0001588978-25-000049","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT Q3 revenue $83.3M (+43% YoY); issues FY2026 guidance $410M-$430M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $83.3M, up 43% YoY; U.S. handpiece/consumables $44.4M (+50% YoY).","Net loss $21.4M vs $21.0M loss prior year; adjusted EBITDA loss $7.4M (vs $12.4M loss).","U.S. install base 653 systems, adding 58 systems in Q3.","FY2025 revenue guidance reaffirmed at ~$325.5M; FY2026 guidance range $410M-$430M.","Gross margin improved to 65% from 63% driven by operational efficiencies."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":231671000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138876,"accession_number":"0001588978-25-000045","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PROCEPT BioRobotics modifies severance for non-CEO execs: severance doubled to 12 months, lump sum on change of control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Severance period for non-CEO execs increased from 6 to 12 months for termination without cause not tied to a change of control.","Upon change of control, performance-based equity awards will vest at no less than target performance level.","Cash severance payments for change of control termination changed from installments to single lump sum.","Eligible executive officers will be asked to sign new agreements reflecting these changes; CEO terms unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138875,"accession_number":"0001588978-25-000041","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT Q2 revenue $79.2M (+48% YoY); raises FY25 guidance; appoints new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $79.2M, up 48% YoY; U.S. handpiece/consumables $43.1M (+58%).","Net loss improved to $19.6M from $25.6M; Adjusted EBITDA loss $8.0M (vs. $17.9M loss prior year).","Gross margin expanded to 65% from 59% due to operational efficiencies and higher system ASP.","Raises FY 2025 revenue guidance to $325.5M (45% growth) from prior $323.0M; expects 64.5% gross margin.","Appoints Larry Wood as CEO effective Sept. 2, 2025; brings 40 years medtech leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":148344000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138874,"accession_number":"0001628280-25-035979","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"PROCEPT BioRobotics appoints Larry Wood as CEO, pre-announces Q2 revenue of $79.2M (+48% YoY)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Larry L. Wood becomes President and CEO effective Sept 2, 2025; succeeds Reza Zadno who retires.","Q2 2025 revenue pre-announced at ~$79.2M, representing 48% year-over-year growth.","Wood receives base salary $925K, target bonus 100% of base, sign-on $1.7M, and equity awards totaling ~$18M.","Zadno enters 18-month consulting agreement; severance includes 12 months base salary and COBRA.","Wood previously served as Corporate VP at Edwards Lifesciences; has been on PROCEPT board since 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156360,"accession_number":"0001588978-25-000038","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Procept BioRobotics stockholders elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Little (31.8M votes for), Prescott (41.7M), Wood (39.8M); broker non-votes 4.35M.","Ratification of PwC as auditor: 46.1M for, 420k against, 28k abstain.","Advisory say-on-pay approved: 40.3M for, 1.9M against, 30k abstain; 4.35M broker non-votes.","All three proposals passed at June 10, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156359,"accession_number":"0001588978-25-000024","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Procept BioRobotics presents at AUA investor event; no financial details in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished presentation slides for AUA annual meeting on April 25, 2025.","Presentation content not provided in full; only title slide included in filing.","No new financial or operational data disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156358,"accession_number":"0001588978-25-000022","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT BioRobotics Q1 revenue up 55% to $69.2M; raises FY2025 guidance to $323M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $69.2M, +55% YoY; U.S. revenue $60.3M (+50%); international $8.9M (+104%).","U.S. handpiece/consumable revenue $38.0M (+61%); U.S. system/rental $18.7M (+31%).","Sold 43 new U.S. robotic systems; install base 547. Gross margin expanded to 64% from 56%.","Net loss $24.7M (vs $26.0M loss YoY); Adjusted EBITDA loss $15.8M (vs $20.4M loss).","FY2025 revenue guidance raised to $323M (+44% YoY); gross margin ~64.5% with possible $5M tariff headwind."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":69162000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174790,"accession_number":"0001588978-25-000004","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT BioRobotics Q4 revenue up 57% to $68.2M; guides FY2025 revenue ~$320M (+42%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 rev $68.2M (+57% YoY); US system rev $27.6M (+67%); handpiece rev $29.3M (+36%).","FY2024 rev $224.5M (+65%); net loss narrowed to $91.4M from $105.9M; adj EBITDA loss $61.1M vs $86.5M.","FY2025 guidance: rev ~$320M (+42%); gross margin ~64.5%; adj EBITDA loss ~$35M.","Cash $333.7M, debt $52.0M; US install base 505 AquaBeam/HYDROS systems.","Q4 saline shortage delayed ~10-20% of Aquablation procedures, impacting handpiece order patterns."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":224498000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191741,"accession_number":"0001628280-24-044544","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PROCEPT BioRobotics issues ~1.92M shares at $91/share, nets ~$163.8M in public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company sold 1,923,076 shares at $91 per share; net proceeds to company were ~$163.8M after discounts and expenses.","Selling stockholder also sold shares; underwriters' overallotment of 288,461 shares was fully exercised on Oct 30.","Company did not receive any proceeds from selling stockholder's sale of shares.","Directors and officers agreed to 60-day lock-up on stock sales without underwriter consent.","Offering closed on October 31, 2024; underwriting agreement includes customary terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191740,"accession_number":"0001588978-24-000027","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT BioRobotics Q3 revenue $58.4M (+66% YoY); raises 2024 revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $58.4M, up 66% YoY; U.S. handpiece+consumables $29.6M (+74%).","Sold 45 U.S. systems at ~$432K ASP; install base reached 445 systems.","Record gross margin 63.2% vs 53.8% a year ago; net loss improved to $21.0M.","Adjusted EBITDA loss narrowed to $12.4M from $19.4M in Q3 2023.","Raised FY2024 revenue guidance to $222.5-223.0M (from $217M); adj. EBITDA loss guidance to ($60.0M) from ($67.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":156262000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208216,"accession_number":"0001628280-24-037969","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"PROCEPT BioRobotics receives FDA 510(k) clearance for HYDROS Robotic System","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["HYDROS features FirstAssist AI for AI-powered treatment planning using real-world procedure data.","System integrates advanced image guidance, digital cystoscopy, and dual HD touchscreens.","Robotic resection uses heat-free waterjet to execute surgeon-defined treatment plans.","Streamlined workflow with single-footprint integrated tower, adjustable touchscreen, and instinctive software.","HYDROS brings next-generation Aquablation therapy, building on insights from over 50,000 procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208215,"accession_number":"0001588978-24-000018","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT BioRobotics Q2 revenue $53.4M (+61% YoY); raises FY2024 revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $53.4M (+61% YoY); U.S. handpiece & consumables $27.3M (+101% YoY).","Net loss $25.6M; Adjusted EBITDA loss $18.0M improved from $19.9M loss in prior period.","Raised FY2024 revenue guidance to ~$217M (from $213.5M); EBITDA loss guidance narrowed to $67.5M from $70M.","Gross margin reached 59% (vs 56% YoY); cash & investments $214.1M; Q2 cash usage $11.5M vs $31.6M in Q1.","Sold 47 U.S. robotic systems in Q2; U.S. install base 400; international revenue $5.7M (+79% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":97892000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208214,"accession_number":"0001628280-24-032343","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Krummel resigns; Thomas M. Prescott appointed new board member and chairperson","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Thomas Krummel resigned from Board and Compensation Committee effective July 18, 2024; no disagreement with company.","Thomas M. Prescott appointed as Board member and Chairperson effective July 18, 2024, filling vacancy.","Prescott is independent; former President and CEO of Align Technology (2002-2015) and held executive roles at Cardiac Pathways and GE Medical.","Prescott's term as Class I director expires at 2025 annual meeting; compensated per standard non-employee director program.","Prescott will enter into company's standard director indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225791,"accession_number":"0001628280-24-026712","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Procept BioRobotics shareholders elect three directors, ratify auditor, approve executive compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amy Dodrill, Taylor Harris, and Reza Zadno elected to board with majority vote.","PricewaterhouseCoopers ratified as independent auditor for FY2024: 43M for, 6.6k against, 68k abstain.","Non-binding advisory vote on named executive officer compensation passed with 37.5M for, 1.3M against, 115k abstain.","Broker non-votes of 4.26M on director election and Say-on-Pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225790,"accession_number":"0001628280-24-020162","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PROCEPT BioRobotics furnishes investor presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company will present at investor conferences starting May 3, 2024, using slides furnished as Exhibit 99.1.","No quarterly results, guidance, or operational metrics are included in the filing excerpt.","Exhibit 99.1 is a set of presentation slides, but its content is not reproduced in the available text.","Filing under Item 7.01 is a routine Reg FD disclosure; no material new information is identifiable.","Ticker PRCT; confidence in material content is low due to missing exhibit details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225789,"accession_number":"0001588978-24-000011","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PROCEPT BioRobotics announces Q1 2024 earnings; press release not included in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["The 8-K filing references a press release dated May 1, 2024 for Q1 2024 financial results.","No specific earnings figures, guidance, or operational data are available in the filing body.","Investors should refer to the full press release, which was furnished but not filed as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":44539000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225788,"accession_number":"0001628280-24-016983","cik":1588978,"company_name":"PROCEPT BioRobotics Corp","ticker":"PRCT","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Colby Wood resigns; Larry Wood appointed to board and audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Colby Wood resigned as director and Audit Committee member effective April 18, 2024; no disagreement cited.","Larry Wood appointed as Class I director and Audit Committee member, term through 2025 annual meeting.","Larry Wood is Group President for Surgical Structural Heart at Edwards Lifesciences with 35+ years in medtech.","Larry Wood will receive standard non-employee director compensation per company's program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1516033313.063492,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}